NRx Finally Has a Drug. The Stock Is Still Down 37%.
On October 29, 2026 — nineteen days before this call — the FDA approved NRx Pharmaceuticals' abbreviated new drug application for preservative-free ketamine. It was the company's first approval, and, by Jonathan Javitt's telling, the first time the agency has cleared a blow-fill-seal vial with a Luer Lock connector as a drug-device combination. Seventeen sales reps went into the field. The first order landed "yesterday."
The Approval, and the Tape That Ignored It
The tape did not care. NRXP closed 2026-11-18 down 37.2% over ninety trading days, 37.5% below its July 22 peak of $4.48, in a single unbroken downtrend. The lifetime chart is worse: down 97.1% since 2017, 99.6% below the February 2021 peak of $627.10 (adjusted). A company can announce the best quarter in its history into a stock that is being repriced for dilution, and this is what that looks like.
The operating numbers, at least, finally point the right direction. Michael Abrams reported “NRx reported net patient revenue of $1.2 million compared with $0.2 million for the third quarter of 2025.” — Michael Abrams, Chief Financial Officer · 2026-11-17 Cash stood at roughly $19.8 million against $7.8 million at year-end, the difference being a public offering of more than $22 million in gross proceeds. The convertible debt that Javitt calls the company's "toxic" inheritance is gone from the balance sheet entirely.
Read the right line, though. The net loss of $2.2 million ($0.05 per share) against a $5.9 million loss a year earlier is a beautiful headline. It is also smaller than the $8.1 million loss from operations reported on the same call, which means roughly $6 million of the improvement came from somewhere below the operating line. The nine-month figures make it plainer: operating losses widened to $19.4 million from $11.6 million, while the nine-month net loss narrowed to $20.1 million from $29 million — the latter flattered by 2025's fair-value charges on the very convertibles NRx has since retired. The last fully-reported quarter in the fundamentals set tells the same story: an operating loss near $7 million against revenue of about $1 million, with R&D up 114% year over year and SG&A up 47%.
Four Companies Inside One Ticker
The structural news of this call is that NRx has stopped being one thing. It is now NeuroRx (sterile injectables plus the NRX-100 depression NDA), HOPE Therapeutics (six clinics in Florida, generating clinical revenue), NRx Defense Systems (an $11.2 million DARPA prime contract to run the SPARC-TMS trial of NRX-101), and GeNeuro (ALS and schizophrenia, built on the theory that the envelope protein of human endogenous retrovirus K is neurotoxic and that an antibody, GNK-301, can sponge it up). The unifying financial logic is that each division is meant to be funded by something other than NRXP equity — government grants, DARPA milestones, a Swiss entity's outside investors.
That is either elegant capital allocation or four underfunded startups sharing a $107 million market cap. The evidence so far: NRxD has satisfied initial milestones with “the first 2 invoices are approved for payment in Q4 2026” — Jonathan Javitt, Founder, Chairman and Chief Executive Officer · 2026-11-17, and GeNeuro's entire value proposition now rests on a Science Day in the first week of December. Note that no other company in this week's reporting cohort is talking about blow-fill-seal manufacturing, sterile injectable reshoring or endogenous retroviruses. This is a genuinely company-unique story, not a sector wave.
What Management Stopped Saying
The most telling change is a word that vanished. KETAFREE — the branded handle NRx used for two years and the top-ranked theme of its 2025 call — was downgraded everywhere in this transcript. Asked point-blank about the name, Javitt replied that "the label says ketamine preservative-free and customers are telling us that they like having a label that says exactly what the drug is." The keyword's own history records the retreat: KETAFREE momentum has collapsed outright. Likewise, patents fell out of the lexicon, replaced by exclusivity and a manufacturing moat.
A recurring theme that we hear from shareholders is the feeling that they've been diluted over the past 2 years as we built a new, hopefully durable and potentially near-term profitable company. In reality, management believes that the owners of approximately 11 million shares that were outstanding in September 2024 today own about 65% more value 2 years later based on their proportionate share in our current enterprise. Over the same period, the S&P 500 increased half that amount, 31%.
That is a striking claim to make to a shareholder base watching a 37% drawdown. It also quietly concedes the dilution it defends against.
Two other notes have been retired. Akathisia and lurasidone, once the entire NRX-101 investment case, are now supporting characters; the drug's future runs through Transcranial Magnetic Stimulation and the military. And the addressable market shrank on the way to approval: the ketamine opportunity was pegged at "$750 million" on the August call and is now “about $400 million a year” — Jonathan Javitt, Founder, Chairman and Chief Executive Officer · 2026-11-17, growing more than 17% — a defensible narrowing to the hospital anesthesia/pain segment, but a narrowing nonetheless.
The Arithmetic Behind the Story
The bull case is a cost-of-goods story. Glass vials run about $3.25 a unit; the blow-fill-seal line runs about $0.75, and 900,000 BFS units fill in the time it takes to bottle 50,000 glass vials. NRx's answer to "what stops a copier" is not a patent but a queue: "“we've just bought 2 of them. So we've kind of bought out the manufacturing capacity for the short term.” — Jonathan Javitt, Founder, Chairman and Chief Executive Officer · 2026-11-17" The optionality sits in a pending Citizen Petition to strip benzethonium chloride from generic ketamine — a generic drug market-clearing event Javitt explicitly refuses to promise.
What is verifiable is thin. On the May call management promised inventory: “At the time of the launch, we'll have at least 1 million units in the warehouse.” — Jonathan Javitt, CEO · 2026-05-18 On this call, inventory was not quantified and the first order's size was deferred to quarter-end. The NRX 200 subcutaneous program, the Yale/PCORI accelerated-approval bridge, and the rolling NDA "by the end of this year" are all forward-dated. The balance sheet, meanwhile, has already been spent once: effective net cash of negative $6 million as of the June quarter, repaired only by equity.
So the real question is not whether NRx crossed a threshold — it did, $1.2 million of revenue and a drug on the market are not nothing. The question is whether a four-division structure funded by five separate non-dilutive sources can reach 2027 profitability before the tape forces the sixth raise. Ninety days of price action say the market has already voted on the answer.